FdaApplication
BLA 761105
Identifiers
- fda_app_no: BLA761105
Properties
| Property | Value |
|---|---|
| applicant_name | AbbVie Inc. |
| application_type | BLA |
| approval_date | 2019-04-23 |
Revenue by product
SKYRIZI
| Period | Revenue |
|---|---|
| Q2 2026 | $5.5B |
| Q1 2026 | $4.5B |
| Q4 2025 | $5.0B |
| Q3 2025 | $4.7B |
| Q2 2025 | $4.4B |
| Q1 2025 | $3.4B |
| Q4 2024 | $3.8B |
| Q3 2024 | $3.2B |
| Q2 2024 | $2.7B |
| Q1 2024 | $2.0B |
| Q4 2023 | $2.4B |
| Q3 2023 | $2.1B |
| Q2 2023 | $1.9B |
| Q1 2023 | $1.4B |
| Q4 2022 | $1.6B |
| Q3 2022 | $1.4B |
| Q2 2022 | $1.3B |
| Q1 2022 | $940.0M |
| Q4 2021 | $895.0M |
| Q3 2021 | $796.0M |
| Q2 2021 | $674.0M |
| Q1 2021 | $574.0M |
| Q4 2020 | $525.0M |
| Q3 2020 | $435.0M |
| Q2 2020 | $330.0M |
| Q1 2020 | $300.0M |
| Q4 2019 | $216.0M |
| Q3 2019 | $91.0M |
| Q2 2019 | $48.0M |
| Q1 2019 | $0.0M |
| Q4 2018 | $0.0M |
| Q3 2018 | $0.0M |
| Q2 2018 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
SKYRIZI
| Period | Revenue |
|---|---|
| Q2 2026 | $5.5B |
| Q1 2026 | $4.5B |
| Q4 2025 | $5.0B |
| Q3 2025 | $4.7B |
| Q2 2025 | $4.4B |
| Q1 2025 | $3.4B |
| Q4 2024 | $3.8B |
| Q3 2024 | $3.2B |
| Q2 2024 | $2.7B |
| Q1 2024 | $2.0B |
| Q4 2023 | $2.4B |
| Q3 2023 | $2.1B |
| Q2 2023 | $1.9B |
| Q1 2023 | $1.4B |
| Q4 2022 | $1.6B |
| Q3 2022 | $1.4B |
| Q2 2022 | $1.3B |
| Q1 2022 | $940.0M |
| Q4 2021 | $895.0M |
| Q3 2021 | $796.0M |
| Q2 2021 | $674.0M |
| Q1 2021 | $574.0M |
| Q4 2020 | $525.0M |
| Q3 2020 | $435.0M |
| Q2 2020 | $330.0M |
| Q1 2020 | $300.0M |
| Q4 2019 | $216.0M |
| Q3 2019 | $91.0M |
| Q2 2019 | $48.0M |
| Q1 2019 | $0.0M |
| Q4 2018 | $0.0M |
| Q3 2018 | $0.0M |
| Q2 2018 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (8)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| SKYRIZI | RISANKIZUMAB-RZAA | 75MG/0.83ML | Injection |
| SKYRIZI | RISANKIZUMAB-RZAA | 150MG/ML | Injection |
| SKYRIZI | — | 180MG/1.2ML (150MG/ML) | Injection |
| SKYRIZI | — | 55MG/0.37ML | Injection |
| SKYRIZI | — | 360MG/2.4ML (150MG/ML) | Injection |
| SKYRIZI | — | 90MG/ML | Injection |
| SKYRIZI | — | 180MG/1.2ML (150MG/ML) | Injection |
| SKYRIZI | — | 150MG/ML | Injection |
8 products